HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon CEO

This article was originally published in The Rose Sheet

Executive Summary

Three-year employment term of President and CEO Jack Stahl, originally scheduled to end Feb. 28, 2005, has been extended to February 28, 2008 under amended employment agreement between Revlon and the exec, according to an 8-K filed with the Securities & Exchange Commission Dec. 17. In recognition of Revlon's and the chief exec's confidence in the "long-term equity value" of the firm, Stahl's stock option and restricted share awards also have been amended. Under the new terms, if the exec is terminated by Revlon without cause or by himself for "good reason," share awards would "continue to vest in accordance with their terms as if his employment had not been terminated," the filing states. The former Coca-Cola exec took the helm at Revlon in 2002, succeeding Jeffrey Nugent (1"The Rose Sheet" Feb. 25, 2002, p. 6)...

You may also be interested in...



Revlon Brand Management Responsibilities To Be Assigned By New CEO Stahl

One of the first tasks facing Revlon's newly-appointed President and CEO Jack Stahl will be delegating management duties for the company's key Revlon brand following the resignation of Revlon Brand Equity Group Exec VP and General Manger Cheryl Vitali

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel